Research Associate – Cellular and Molecular Biology – Cambridge

Regel Therapeutics is a gene modulation therapy company focused on improving the life of patients suffering from disorders resulting from alteration of gene expression. Our proven T3 (Targeted Therapeutic Technology) platform combines AAV delivery with two proprietary technologies for efficient and specific restoration of gene expression exclusively in the cells affected by the pathology. We are a seed-stage startup based in Cambridge, MA and Berkeley, CA and we are looking for a talented Research Associate to join our R&D team to help develop our preclinical programs.

Location

Cambridge, MA

Role Responsibilities

  • Perform proof-of-concept experiments in cell lines to support preclinical development efforts
  • Maintain precious human induced pluripotent stem cell cultures and perform complex differentiation protocols
  • Implement in vitro screening and validation methodology
  • Analyze experimental results and communicate research findings to leadership
  • Maintain accurate and detailed documentation of activities

Required Qualifications

  • B.S./M.S. in cellular biology, developmental biology, molecular biology, or related field
  • Strong molecular biology skills including DNA/RNA extraction, qPCR, and molecular cloning
  • Experience with mammalian cell culture methods and sterile technique
  • Experience with cell biology techniques including immunofluorescence staining and microscopy
  • Excellent written and oral communication skills
  • Proven track record of working in collaborative environments and in a team

Preferred Qualifications

  • Experience with pluripotent stem cell differentiation protocols using organoids
  • Experience producing libraries for bulk or single cell RNA sequencing
  • Basic computational biology skills to interpret differential expression analysis
  • Background in neuroscience/neurobiology or muscle/cardiovascular biology
  • Previous experience working with AAVs and lentiviruses

Categorias:

July 23, 2021 6:45 pm Publicado por: